|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines
Andrea König,
Gary K. Schwartz,
Ramzi M. Mohammad,
Ayad Al-Katib, and
Janice L. Gabrilove
From The Molecular Therapeutics Program, the Sloan-Kettering Institute; the Department of Medicine, the Division of Hematology-Oncology and the Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center; New York, NY; and the Division of Hematology and Oncology, the Department of Internal Medicine, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI.
Flavopiridol is a novel, potent inhibitor of cyclin-dependent kinases (CDK). This synthetic flavone has been reported to exhibit antitumor activity in murine and human tumor cell lines in vitro and in vivo and is currently undergoing clinical phase I evaluation. In the present study, 1 Epstein-Barr virus (EBV)-transformed B-prolymphocytic cell line (JVM-2), 1 EBV-transformed B-CLL cell line (I83CLL), and 1 non-EBV transformed B-CLL cell line (WSU-CLL) were used as targets. Treatment of the cells with flavopiridol (100 nmol/L to 400 nmol/L) led to a marked dose- and time-dependent inhibition of cell growth and survival as determined using trypan blue exclusion. Morphologic analysis showed characteristic apoptotic changes such as chromatin condensation and fragmentation, membrane blebbing, and formation of apoptotic bodies. Furthermore, quantitative assessment of apoptosis-associated DNA strand breaks by in situ TdT labeling showed that a significant number of flavopiridol-treated cells underwent apoptosis. These cellular effects were associated with a significant decrease in bcl-2 expression as observed by Northern and Western blotting. The results showed that flavopiridol downregulates bcl-2 mRNA and bcl-2 protein expression within 24 hours. Genistein and quercetin, two flavonoids that do not inhibit CDKs, did not affect bcl-2 expression. These data suggest an additional mechanism of action of this new flavone which might be useful as an agent in the treatment of chronic lymphoid malignancies.
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4307-4312
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E.-S. A. Arafa, Q. Zhu, B. M. Barakat, G. Wani, Q. Zhao, M. A. El-Mahdy, and A. A. Wani
Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling Pathway
Cancer Res.,
December 1, 2009;
69(23):
8910 - 8917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takada, G. Sethi, B. Sung, and B. B. Aggarwal
Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid Cells
Mol. Pharmacol.,
May 1, 2008;
73(5):
1549 - 1557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, T. S. Lin, J. T. Dalton, D. Wu, M. A. Phelps, B. Fischer, M. Moran, K. A. Blum, B. Rovin, M. Brooker-McEldowney, et al.
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
Blood,
January 15, 2007;
109(2):
399 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Palacios, R. Yerbes, and A. Lopez-Rivas
Flavopiridol Induces Cellular FLICE-Inhibitory Protein Degradation by the Proteasome and Promotes TRAIL-Induced Early Signaling and Apoptosis in Breast Tumor Cells.
Cancer Res.,
September 1, 2006;
66(17):
8858 - 8869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. I. Shapiro
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
J. Clin. Oncol.,
April 10, 2006;
24(11):
1770 - 1783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. K. Lee, C. R. Isham, S. H. Kaufman, and K. C. Bible
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy
Mol. Cancer Ther.,
January 1, 2006;
5(1):
138 - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Whitlock, M. Krailo, J. M. Reid, S. L. Ruben, M. M. Ames, W. Owen, and G. Reaman
Phase I Clinical and Pharmacokinetic Study of Flavopiridol in Children With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol.,
December 20, 2005;
23(36):
9179 - 9186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Schwartz and M. A. Shah
Targeting the Cell Cycle: A New Approach to Cancer Therapy
J. Clin. Oncol.,
December 20, 2005;
23(36):
9408 - 9421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Bible, J. L. Lensing, S. A. Nelson, Y. K. Lee, J. M. Reid, M. M. Ames, C. R. Isham, J. Piens, S. L. Rubin, J. Rubin, et al.
Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points
Clin. Cancer Res.,
August 15, 2005;
11(16):
5935 - 5941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Schwartz
Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy
J. Clin. Oncol.,
July 10, 2005;
23(20):
4499 - 4508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Brown
Chronic Lymphocytic Leukemia: A Niche for Flavopiridol?
Clin. Cancer Res.,
June 1, 2005;
11(11):
3971 - 3973.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, B. L. Peterson, J. Gabrilove, O. M. Odenike, M. R. Grever, K. Rai, R. A. Larson, and the Cancer and Leukemia Group B
Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805
Clin. Cancer Res.,
June 1, 2005;
11(11):
4176 - 4181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Richard, D. Matthews, W. Duivenvoorden, J. Yau, P. S. Wright, and J. P.H. Th'ng
Flavopiridol Sensitivity of Cancer Cells Isolated from Ascites and Pleural Fluids
Clin. Cancer Res.,
May 1, 2005;
11(9):
3523 - 3529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Puppo, S. Pastorino, G. Melillo, A. Pezzolo, L. Varesio, and M. C. Bosco
Induction of Apoptosis by Flavopiridol in Human Neuroblastoma Cells Is Enhanced under Hypoxia and Associated With N-myc Proto-oncogene Down-Regulation
Clin. Cancer Res.,
December 15, 2004;
10(24):
8704 - 8719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. N. Demidenko and M. V. Blagosklonny
Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor
Cancer Res.,
May 15, 2004;
64(10):
3653 - 3660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takada and B. B. Aggarwal
Flavopiridol Inhibits NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of I{kappa}B{alpha} Kinase and p65 Phosphorylation: ABROGATION OF CYCLIN D1, CYCLOOXYGENASE-2, AND MATRIX METALLOPROTEASE-9
J. Biol. Chem.,
February 6, 2004;
279(6):
4750 - 4759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Aklilu, H. L. Kindler, R. C. Donehower, S. Mani, and E. E. Vokes
Phase II study of flavopiridol in patients with advanced colorectal cancer
Ann. Onc.,
August 1, 2003;
14(8):
1270 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bevilacqua, M. C. Ceriani, G. Canti, L. Asnaghi, R. Gherzi, G. Brewer, L. Papucci, N. Schiavone, S. Capaccioli, and A. Nicolin
Bcl-2 Protein Is Required for the Adenine/Uridine-rich Element (ARE)-dependent Degradation of Its Own Messenger
J. Biol. Chem.,
June 20, 2003;
278(26):
23451 - 23459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Kouroukis, A. Belch, M. Crump, E. Eisenhauer, R. D. Gascoyne, R. Meyer, R. Lohmann, P. Lopez, J. Powers, R. Turner, et al.
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol.,
May 1, 2003;
21(9):
1740 - 1745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wittmann, P. Bali, S. Donapaty, R. Nimmanapalli, F. Guo, H. Yamaguchi, M. Huang, R. Jove, H. G. Wang, and K. Bhalla
Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis
Cancer Res.,
January 1, 2003;
63(1):
93 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ma, W. D. Cress, and E. B. Haura
Flavopiridol-induced Apoptosis Is Mediated through Up-Regulation of E2F1 and Repression of Mcl-1
Mol. Cancer Ther.,
January 1, 2003;
2(1):
73 - 81.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas
Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial
Clin. Cancer Res.,
January 1, 2003;
9(1):
307 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gojo, B. Zhang, and R. G. Fenton
The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1
Clin. Cancer Res.,
November 1, 2002;
8(11):
3527 - 3538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Tan, D. Headlee, R. Messmann, E. A. Sausville, S. G. Arbuck, A. J. Murgo, G. Melillo, S. Zhai, W. D. Figg, S. M. Swain, et al.
Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
J. Clin. Oncol.,
October 1, 2002;
20(19):
4074 - 4082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. A. Elsayed and E. A. Sausville
Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins
Oncologist,
December 1, 2001;
6(6):
517 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Schwartz, D. Ilson, L. Saltz, E. O'Reilly, W. Tong, P. Maslak, J. Werner, P. Perkins, M. Stoltz, and D. Kelsen
Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma
J. Clin. Oncol.,
April 1, 2001;
19(7):
1985 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Bible, R. H. Bible Jr., T. J. Kottke, P. A. Svingen, K. Xu, Y.-P. Pang, E. Hajdu, and S. H. Kaufmann
Flavopiridol Binds to Duplex DNA
Cancer Res.,
May 1, 2000;
60(9):
2419 - 2428.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. M. Senderowicz and E. A. Sausville
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
J Natl Cancer Inst,
March 1, 2000;
92(5):
376 - 387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Bible, S. A. Boerner, K. Kirkland, K. L. Anderl, D. Bartelt Jr., P. A. Svingen, T. J. Kottke, Y. K. Lee, S. Eckdahl, P. G. Stalboerger, et al.
Characterization of an Ovarian Carcinoma Cell Line Resistant to Cisplatin and Flavopiridol
Clin. Cancer Res.,
February 1, 2000;
6(2):
661 - 670.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W. M. Stadler, N. J. Vogelzang, R. Amato, J. Sosman, D. Taber, D. Liebowitz, and E. E. Vokes
Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study
J. Clin. Oncol.,
January 14, 2000;
18(2):
371 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, M. Bhuiyan, S. Alhasan, A. M. Senderowicz, and F. H. Sarkar
Induction of Apoptosis and Inhibition of c-erbB-2 in Breast Cancer Cells by Flavopiridol
Clin. Cancer Res.,
January 1, 2000;
6(1):
223 - 229.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. I. Shapiro, D. A. Koestner, C. B. Matranga, and B. J. Rollins
Flavopiridol Induces Cell Cycle Arrest and p53-independent Apoptosis in Non-Small Cell Lung Cancer Cell Lines
Clin. Cancer Res.,
October 1, 1999;
5(10):
2925 - 2938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ruef, A. S. Meshel, Z. Hu, C. Horaist, C. A. Ballinger, L. J. Thompson, V. D. Subbarao, J. A. Dumont, and C. Patterson
Flavopiridol Inhibits Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo After Carotid Injury in the Rat
Circulation,
August 10, 1999;
100(6):
659 - 665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Kottke, A. L. Blajeski, L. M. Martins, P. W. Mesner Jr., N. E. Davidson, W. C. Earnshaw, D. K. Armstrong, and S. H. Kaufmann
Comparison of Paclitaxel-, 5-Fluoro-2'-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis. EVIDENCE FOR EGF-INDUCED ANOIKIS
J. Biol. Chem.,
May 28, 1999;
274(22):
15927 - 15936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, C. Shinn, J. K. Waselenko, E. J. Fuchs, T. A. Lehman, P. L. Nguyen, I. W. Flinn, L. F. Diehl, E. Sausville, and M. R. Grever
Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Dependence on Functional p53
Blood,
November 15, 1998;
92(10):
3804 - 3816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mohr, T. S. McCormick, and E. G. Lapetina
Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: Dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059
PNAS,
April 28, 1998;
95(9):
5045 - 5050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. V. Achenbach, R. Muller, and E. P. Slater
Bcl-2 Independence of Flavopiridol-induced Apoptosis. MITOCHONDRIAL DEPOLARIZATION IN THE ABSENCE OF CYTOCHROME c RELEASE
J. Biol. Chem.,
October 6, 2000;
275(41):
32089 - 32097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
